The aim of this study was to evaluate the safety of long-term treatment with tiagabine. We reviewed the case report forms of patients with refractory partial epilepsy who took tiagabine for longer than 6 months in two long-term studies. We classified all adverse events based on severity and persistence, and recorded the dose at onset of each adverse event. We then divided patients into those treated for 6-12 months, 12-24 months and >24 months. We compared the adverse event profile and change in seizure frequency among the three groups. Forty-two patients took tiagabine for longer than 6 months. The mean duration of treatment was 22.6 months. The mean monthly seizure frequency was 12.7 at baseline and 8.1 at study termination (36% decrease). The most common adverse events were: tiredness (56%), headache (46%), dizziness (44%), visual symptoms (blurring, difficulty focusing, diplopia) (39%), altered mentation (32%), and tremor (31%). The adverse event profile was comparable among the three groups. Seizure frequency was significantly more improved in the >24 months group. Long-term treatment with tiagabine is well tolerated. The most important predictor of long-term therapy with tiagabine was the degree of seizure improvement.
INTRODUCTION
Tiagabine (Gabitril) is a novel antiepileptic agent approved for use in the USA since 1997 1 . It is a nipecotic acid derivative with high bioavailability (90-95%), dose-independent absorption, high protein binding (96%), first-order elimination pharmacokinetics, and it is metabolized extensively through the hepatic cytochrome P450 enzyme system 2, 3 . The mechanism of action is through selective binding to a GABA uptake carrier (GAT-1), therefore inhibiting the reuptake of GABA to neurons and glia 4, 5 . Its efficacy against partial seizures and its side-effect profile have been well detailed in several reports [6] [7] [8] [9] [10] [11] [12] [13] . Less has been published about the long-term use of tiagabine [8] [9] [10] . We report our experience with the safety of long-term tiagabine therapy in patients with refractory epilepsy.
MATERIALS AND METHODS
We reviewed the results of two long-term, openlabel studies of tiagabine in refractory partial epilepsy in two centers. We concentrated on patients who took the medication for 6 months or longer and reviewed their case-report forms and medical records. We recorded age, gender, type(s) of seizures and number of antiepileptic drugs (AEDs) previously tried. We recorded the baseline AED(s) and noted any change in these medications during the studies. We noted seizure frequency at baseline and at study termination. We also recorded the duration of treatment with tiagabine and the dose used for the longest period of time. We looked at the maximum dose of tiagabine achieved for each patient and the reason for its discontinuation when applicable.
We evaluated all adverse events encountered during the studies. We divided adverse events into major categories based on symptoms reported. The category of 'tiredness', for example, included sleepiness, drowsiness, decreased energy, and sluggishness. The term 'dizziness' encompassed vertigo, unsteadiness, and a 'drugged feeling'. Visual symptoms included blurred vision, diplopia, and decreased visual focus. Gastrointestinal symptoms included nausea, vomit-ing, diarrhea, constipation, and abdominal discomfort. Nervousness also referred to shakiness and jitters, whereas emotional lability included feeling 'high' as well as depression. The term 'altered mentation' included complaints of a 'blank feeling', confusion, and/or disorientation. We then classified all adverse events based on severity (mild-moderate-severe) and persistence (transient-persistent). We also recorded the dose of tiagabine at the onset of each adverse event.
We then divided the patients into three groups based on the duration of treatment with tiagabine; patients who took the drug for 6-12 months (19 patients, mean duration of treatment = 8 months), patients who took the drug for 12-24 months (6, mean duration of treatment = 15 months), and those who took the drug for greater than 24 months (17, mean duration of treatment = 43 months). The two largest groups were those who took the drug for 6-12 months and greater than 24 months. We compared these two groups for age, gender, number of AEDs previously tried, number of AEDs at baseline, and change in AEDs during the studies as well as seizure frequency at baseline and study termination. We also compared the adverse event profile among the two groups, including the dose at onset, frequency, and persistence.
We used the chi-squared method and Fisher's exact test for statistical analysis.
RESULTS
A total of 59 patients in two centers received tiagabine as a part of various studies of the treatment of partial seizures. Four patients who participated in the doubleblind phase of a dose-response trial exited without enrollment in the long-term, open-label extension of the study. The other 55 patients participated in two longterm studies of tiagabine in the treatment of refractory partial seizures. Forty-two of those 55 patients (76%) took tiagabine for longer than 6 months and constituted the study population. There were 24 females and 18 males; the mean age was 36 years (range: 13-70). They had previously tried an average of 5.5 AEDs prior to enrollment in a tiagabine study. The most common baseline AEDs were carbamazepine (21 patients), phenytoin (16 patients) and divalproex sodium (ten patients). At baseline, 26 patients were on one AED, 14 were on two AEDs, and one patient was on three AEDs. Twenty-nine of 42 patients remained on the same baseline AEDs during the course of the study. Of these 29 patients, 19 were on one AED, nine were on two AEDs, and one was on three. Among the other 12 patients, five were on two AEDs and reduced to one drug, four were on one AED and changed to a different drug, one was on one AED and changed to a different drug and two patients were on one AED and added another drug.
The mean duration of treatment with tiagabine was 22.5 months for all patients. The mean dose of tiagabine that patients took for the longest time was 49 mg d −1 . The dose of tiagabine taken for the longest period of time did not necessarily represent the highest dose achieved; the mean maximal dose was 59 mg d −1 . The mean monthly seizure frequency was 12.7 at baseline and 8.1 at the end of follow-up, this represented a 36% decrease in seizure frequency. The median monthly seizure frequency was seven at baseline and four at the end of follow-up (43% decrease).
The most common adverse events were tiredness, headache, dizziness, visual symptoms, altered mentation, tremor, memory problems, gastrointestinal symptoms, nervousness, paresthesias, and emotional lability (Table 1) . Less common adverse events were insomnia (four patients), decreased concentration (three patients), tinnitus (three patients), auditory hallucinations (one patient), generalized stiffness (one patient), and speech disturbance (one patient). Adverse events were mostly mild to moderate in intensity and transient in nature. Reducing tiagabine or concomitant AED doses relieved most adverse events. Only three patients discontinued the medication because of adverse events.
One particular adverse event, altered mentation, occurred in 13 patients (32%). This was generally described as episodes of confusion or a blank feeling. Four patients had associated decreased responsiveness and subtle twitching of one or more limbs, which started at a mean dose of 51 mg d −1 . An EEG obtained in two of these patients showed concomitant generalized bisynchronous rhythmic slow wave activity. No patient acutely responded to repeated doses of benzodiazepines. One patient consequently discontinued tiagabine. The others had significant reduction in seizure frequency and as a result only reduced the dose of tiagabine (two patients) or the concomitant AED (one patient) with improvement or resolution of symptoms.
Comparison of the two largest groups of patients (6-12 months and greater than 24 months) revealed similar demographic data ( Table 2 ). The only major difference was the degree of improvement in seizure control, which was significantly in favor of the greater than 24 months groups. The adverse event profile was also generally comparable among the two groups (Table 3). Only emotional lability occurred significantly more frequently in the greater than 24 months group.
DISCUSSION
We report our experience with long-term treatment of refractory epilepsy with tiagabine. In our series, 76% of patients with refractory epilepsy who were exposed to tiagabine and entered an extension study continued the medication for longer than 6 months. The most common adverse events related to the central nervous system and were tiredness, headache, dizziness, visual symptoms, altered mentation, tremor, and memory problems. They were, therefore, generally comparable to previous reports [6] [7] [8] [9] [10] [11] [12] [13] . All but one of our patients were on at least one other AED, and one of the disadvantages of add-on trials is the tendency to overestimate adverse events 14 . However, the safety profile of tiagabine has been similar in both add-on 6, [8] [9] [10] [11] [12] [13] and monotherapy studies 7 . Overall, in the clinical trials, 21% of patients discontinued the medication because of adverse events, most commonly dizziness, somnolence, depression, confusion, and asthenia 2 . Our findings are somewhat similar, with dizziness, decreased memory, altered mentation and headache causing discontinuation of the drug after long-term therapy in three patients (7%). The smaller number of patients discontinuing the drug because of adverse events in our series may reflect the open-label nature of the trials where frequent adjustments of doses of medications are possible. In addition, only patients who were treated for 6 months or more were included in this study, and adverse effects resulting in discontinuation may be more likely early in therapy. Adverse events were mostly mild to moderate in severity, transient in nature, and occurred at relatively large doses of tiagabine. In fact, the mean daily dose of tiagabine used for the longest period of times was 49 mg, which approaches the higher end of the recommended dose range (32-56 mg d −1 ) for patients on concurrent hepatic enzyme-inducing AEDs 15 . One specific adverse event, altered mentation, has received particular attention with some reports suggesting that it may represent a form of non-convulsive status epilepticus (NCSE) [16] [17] [18] [19] . The evidence for NCSE was given in some case reports of NCSE in association with TGB therapy [16] [17] [18] [19] . In some instances there was no EEG confirmation of the suspected diagnosis 16 , and where the EEG was performed during the episode the published figures can be interpreted as showing bisynchronous slow wave activity consistent with encephalopathy [17] [18] [19] . NCSE may be a rare occurrence with TGB therapy 20 comparable in incidence to other cohorts of patients with epilepsy followed over a long period of time 21 . Our experience suggests that in the majority of patients this adverse event may represent a dose-related encephalopathic state due to intolerance of tiagabine itself or in combination with other AEDs rather than NCSE. Abou-Khalil 22 reported two patients with prolonged episodes of altered mental status, twitching of upper extremities and concomitant EEG showing rhythmic generalized slow waves intermixed with sharp waves and no response to lorazepam in one. Both patients were then monitored with continuous video-EEG following withdrawal of their AEDs; both had only non-epileptic spells and no evidence for epilepsy. This further suggests that the manifestations reported represent an encephalopathic state induced by tiagabine rather than NCSE. Another group of adverse effects that are of interest are the visual symptoms. Vigabatrin, another GABAergic agent has been associated with visual field constriction, as well as other manifestations reflecting retinal toxicity. Our patients experienced visual symptoms commonly encountered with other AEDs, mainly blurring of vision, difficulty focusing, and diplopia. There are now two reports indicating lack of occurrence of visual constriction with long-term use of tiagabine 22, 23 .
An interesting finding in our study was the similarity of adverse events encountered in patients who took tiagabine for 6-12 months and those who took it for longer than 2 years. There was no significant difference in the safety profile among the two groups both in terms of the types and frequency of individual adverse events. Emotional lability, which seemed to occur more frequently in the longer treated group, was mostly transient (75%). Longer duration of treatment with tiagabine, therefore, generally does not seem to predispose patients to greater frequency or severity of adverse events. Patients who took the medication for greater than 2 years had significantly less seizures than those who took it for 6-12 months (52% vs. 10.9% reduction, respectively). Therefore, the degree of improvement in seizure control and not adverse events was the most important predictor of long-term therapy with tiagabine in our group.
Although the safety of tiagabine was recently reported in detail 10 , our study adds valuable information. We emphasized long-term therapy (>6 months) and found that it did not result in emergence of new, unexpected adverse events. We found that long-term treatment with relatively high doses of tiagabine is well tolerated in patients with refractory epilepsy. We also compared the safety and efficacy of tiagabine among patients with variable duration of exposure to the agent and found that long-term therapy was mostly dependent on improvement of seizure frequency. Continued assessment of long-term safety is important for all new AEDs. The absence of cumulative or unexpected late toxicity will improve neurologists' comfort level with the use of these agents.
